BANNOCKBURN, Ill., July 08, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2024 on Wednesday, July 31, 2024 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day.
Conference Call Details
Participants can pre-register for the conference call at the following link: https://register.vevent.com/register/BId5e0db240b9c416cbbdba9d2afe4b745. The call can also be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at www.OptionCareHealth.com.
For Investor Inquiries:
Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$23.13 |
Daily Change: | 0.64 2.85 |
Daily Volume: | 1,252,456 |
Market Cap: | US$3.960B |
October 30, 2024 July 31, 2024 April 23, 2024 February 22, 2024 January 08, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB